Rüdiger Eming
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rüdiger Eming has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Michael Hertl
Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
10 shared publications- Michael Hertl
Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
6 shared publications Angela Nagel
Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany; Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
4 shared publications- Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
4 shared publications - Michael Sticherling
Hautklinik, Deutsches Zentrum Immuntherapie, Universitätsklinikum Erlangen, Erlangen, Deutschland
4 shared publications - Detlef Zillikens
Klinik für Dermatologie, Allergologie und Venerologie, Universität zu Lübeck
3 shared publications
Latest Publications
- Open Access
- 14 June 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1375
Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare blistering disease caused by IgG autoantibodies against the epidermal adhesion molecules desmoglein (Dsg)3 and Dsg1 providing a well-characterized paradigm of an antibody-mediated organ-specific autoimmune disease. In PV patients who have achieved clinical remission after B cell-depleting therapy, relapses often coincide with a reoccurrence of B cells and Dsg-specific autoantibodies. Here, we analyzed Dsg3-specific B cell subpopulations (i.e., total CD19+ B cells, CD19+CD27−B cells, CD19+CD27+ memory B cells, and CD19+CD27hiCD38hi plasmablasts) in peripheral blood of both PV patients (n = 14) at different stages of disease and healthy individuals (n = 14) by flow cytometry using fluorescently labeled recombinant human Dsg3 protein. Applying this approach, Dsg3-specific B cells could be detected at low frequencies (0.11–0.53% of CD19+ B cells) and numbers of Dsg3-specific memory B cells were significantly increased in PV patients in clinical remission receiving minimal immunosuppressive therapy. Finally, we confirmed in vitro that Dsg3-reactive memory B cells were able to produce anti-Dsg3 IgG autoantibodies upon ex vivo activation. Thus, monitoring of Dsg3-specific B cells in PV is of particular interest to further characterize the immunopathogenesis of PV.
- 14 June 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1375
Open AccessIdentification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare blistering disease caused by IgG autoantibodies against the epidermal adhesion molecules desmoglein (Dsg)3 and Dsg1 providing a well-characterized paradigm of an antibody-mediated organ-specific autoimmune disease. In PV patients who have achieved clinical remission after B cell-depleting therapy, relapses often coincide with a reoccurrence of B cells and Dsg-specific autoantibodies. Here, we analyzed Dsg3-specific B cell subpopulations (i.e., total CD19+ B cells, CD19+CD27−B cells, CD19+CD27+ memory B cells, and CD19+CD27hiCD38hi plasmablasts) in peripheral blood of both PV patients (n = 14) at different stages of disease and healthy individuals (n = 14) by flow cytometry using fluorescently labeled recombinant human Dsg3 protein. Applying this approach, Dsg3-specific B cells could be detected at low frequencies (0.11–0.53% of CD19+ B cells) and numbers of Dsg3-specific memory B cells were significantly increased in PV patients in clinical remission receiving minimal immunosuppressive therapy. Finally, we confirmed in vitro that Dsg3-reactive memory B cells were able to produce anti-Dsg3 IgG autoantibodies upon ex vivo activation. Thus, monitoring of Dsg3-specific B cells in PV is of particular interest to further characterize the immunopathogenesis of PV.
- 5 November 2018
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 16 (11) , 1339-1360
Bullöse Autoimmundermatosen
- 5 November 2018
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 16 (11) , 1339-1360
Bullöse Autoimmundermatosen
- 1 January 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (1) , e1-e6
Research Techniques Made Simple: Mouse Models of Autoimmune Blistering Diseases
- 1 January 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (1) , e1-e6
Research Techniques Made Simple: Mouse Models of Autoimmune Blistering Diseases
- Open Access
- 12 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148919
Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus
Pemphigus is an autoimmune disease in which IgG auto-antibodies (auto-ab) against the desmosomal cadherins desmoglein (Dsg) 3 and Dsg1 cause loss of epidermal keratinocyte adhesion. Aim of this study was to investigate cytokines derived from antigen-presenting cells (APC) and their relation to CD4+ T cell subpopulations and to the auto-ab response in pemphigus. In this regard, patients with pemphigus were compared to patients with myasthenia gravis (MG), an unrelated auto-ab–mediated autoimmune disease, and healthy controls. In pemphigus and MG, the plasma concentrations of the APC-derived immunomodulatory cytokine IL-27 were highly increased. Strikingly, IL-27 strongly correlated with Dsg-specific IgG auto-ab titers. T helper (Th) 17 cells were augmented in both pemphigus and MG patients while T follicular helper (Tfh) cells, which are essential in providing B cell help, were increased only in pemphigus along with increasing plasma concentrations of IL-21, a cytokine produced by Th17 and Tfh cells. Moreover, we could detect Dsg3-specific autoreactive T cells producing IL-21 upon ex vivo stimulation with Dsg3. These findings suggest that IL-27 and IL-21-producing T cells, are involved in the pathogenesis of pemphigus. The further characterization of IL-21-producing T cells and of the role of IL-27 will lead to a more defined understanding of the auto-ab response in pemphigus.
- 12 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148919
Open AccessIncreased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus
Pemphigus is an autoimmune disease in which IgG auto-antibodies (auto-ab) against the desmosomal cadherins desmoglein (Dsg) 3 and Dsg1 cause loss of epidermal keratinocyte adhesion. Aim of this study was to investigate cytokines derived from antigen-presenting cells (APC) and their relation to CD4+ T cell subpopulations and to the auto-ab response in pemphigus. In this regard, patients with pemphigus were compared to patients with myasthenia gravis (MG), an unrelated auto-ab–mediated autoimmune disease, and healthy controls. In pemphigus and MG, the plasma concentrations of the APC-derived immunomodulatory cytokine IL-27 were highly increased. Strikingly, IL-27 strongly correlated with Dsg-specific IgG auto-ab titers. T helper (Th) 17 cells were augmented in both pemphigus and MG patients while T follicular helper (Tfh) cells, which are essential in providing B cell help, were increased only in pemphigus along with increasing plasma concentrations of IL-21, a cytokine produced by Th17 and Tfh cells. Moreover, we could detect Dsg3-specific autoreactive T cells producing IL-21 upon ex vivo stimulation with Dsg3. These findings suggest that IL-27 and IL-21-producing T cells, are involved in the pathogenesis of pemphigus. The further characterization of IL-21-producing T cells and of the role of IL-27 will lead to a more defined understanding of the auto-ab response in pemphigus.
- 1 August 2015
- Published by Springer Nature in Die Dermatologie
- Vol. 66 (8) , 574-582
Pemphigus
Pemphigus ist eine schwere bullöse Autoimmundermatose, deren Behandlung trotz hoch dosierter immunsuppressiver Therapieverfahren aufgrund der iatrogenen Komorbiditäten und der mangelnden langfristigen Wirksamkeit eine klinische Herausforderung darstellt. Welche zielgerichteten Therapieverfahren werden beim Pemphigus bereits eingesetzt und welche innovativen Therapiestrategien befinden sich in der Entwicklung? Es erfolgten eine Literaturrecherche in PubMed unter Berücksichtigung der aktuellen Leitlinie zur Therapie des Pemphigus und eigener Untersuchungen sowie eine Diskussion von Grundlagenarbeiten und Einbeziehung von neuen zielgerichteten Therapien bei Autoantikörper-vermittelten Autoimmunerkrankungen. Immunapherese und hoch dosierte intravenöse Immunglobuline, die auf eine Reduktion von zirkulierenden Autoantikörpern ausgerichtet sind, werden bereits erfolgreich in der Behandlung des Pemphigus eingesetzt. Die Depletion von autoreaktiven B-Lymphozyten ist die Rationale für den Einsatz des monoklonalen Anti-CD20-Antikörpers Rituximab, der in klinischen Studien zu lang anhaltenden klinischen Remissionen beim Pemphigus geführt hat. Aktuelle Entwicklungen beinhalten die Prüfung humanisierter B-Zell-depletierender Antikörper bei anderen B-Zell-vermittelten Autoimmunerkrankungen und die Identifizierung von neuen zellulären und molekularen Zielstrukturen, die essenziell für die humorale Autoimmunantwort sind bzw. wichtige immunregulatorische Funktionen ausüben. Die grundlegend gut definierte Pathogenese des Pemphigus resultiert in zielgerichteten Therapieansätzen. Derzeit werden bereits Verfahren eingesetzt, die auf eine rasche Reduktion von zirkulierenden Autoantikörpern bzw. auf eine Depletion von autoreaktiven B-Zellen abzielen. Weitere zelluläre und molekulare Zielstrukturen werden in anderen Autoantikörper-vermittelten Autoimmunerkrankungen untersucht und stellen vielversprechende Kandidaten für innovative, pathogenesebasierte Therapiestrategien beim Pemphigus dar. Pemphigus is a severe bullous autoimmune dermatosis that represents a clinical challenge despite high-dose immunosuppressive therapy due to the therapy-related comorbidities and the lack of long-term control of disease activity. Which targeted therapies are currently used in pemphigus and which innovative therapeutic strategies are in clinical development? A review of the literature in PubMed was performed under consideration of the current guideline for the treatment of pemphigus as well as of our own results. Discussion of basic findings and results of targeted therapies in autoantibody-mediated autoimmune disorders were taken into account. Immunapheresis and high-dose intravenous immunoglobulins with the aim of reducing circulating autoantibodies have been successfully used in the treatment of pemphigus. Depletion of autoreactive B-lymphocytes provides the rationale for the use of the monoclonal anti-CD20 antibody rituximab which demonstrated long-term clinical remission of pemphigus in clinical trials. Current developments include the investigation of humanised B-cell depleting antibodies in other B-cell driven autoimmune disorders as well as the identification of new cellular and molecular target structures that are essential in the humoral autoimmune cascade and exert important immune regulatory functions, respectively. The well-characterised basic pathogenesis of pemphigus results in targeted therapies. Currently, therapies aiming at rapid reduction of circulating autoantibodies and the depletion of autoreactive B-cells are in clinical use. More cellular and molecular target structures are being investigated in other autoantibody-driven autoimmune disorders and they provide promising candidates for innovative pathogenesis-related therapeutic strategies in pemphigus in the future.
- 1 August 2015
- Published by Springer Nature in Die Dermatologie
- Vol. 66 (8) , 574-582
Pemphigus
Pemphigus ist eine schwere bullöse Autoimmundermatose, deren Behandlung trotz hoch dosierter immunsuppressiver Therapieverfahren aufgrund der iatrogenen Komorbiditäten und der mangelnden langfristigen Wirksamkeit eine klinische Herausforderung darstellt. Welche zielgerichteten Therapieverfahren werden beim Pemphigus bereits eingesetzt und welche innovativen Therapiestrategien befinden sich in der Entwicklung? Es erfolgten eine Literaturrecherche in PubMed unter Berücksichtigung der aktuellen Leitlinie zur Therapie des Pemphigus und eigener Untersuchungen sowie eine Diskussion von Grundlagenarbeiten und Einbeziehung von neuen zielgerichteten Therapien bei Autoantikörper-vermittelten Autoimmunerkrankungen. Immunapherese und hoch dosierte intravenöse Immunglobuline, die auf eine Reduktion von zirkulierenden Autoantikörpern ausgerichtet sind, werden bereits erfolgreich in der Behandlung des Pemphigus eingesetzt. Die Depletion von autoreaktiven B-Lymphozyten ist die Rationale für den Einsatz des monoklonalen Anti-CD20-Antikörpers Rituximab, der in klinischen Studien zu lang anhaltenden klinischen Remissionen beim Pemphigus geführt hat. Aktuelle Entwicklungen beinhalten die Prüfung humanisierter B-Zell-depletierender Antikörper bei anderen B-Zell-vermittelten Autoimmunerkrankungen und die Identifizierung von neuen zellulären und molekularen Zielstrukturen, die essenziell für die humorale Autoimmunantwort sind bzw. wichtige immunregulatorische Funktionen ausüben. Die grundlegend gut definierte Pathogenese des Pemphigus resultiert in zielgerichteten Therapieansätzen. Derzeit werden bereits Verfahren eingesetzt, die auf eine rasche Reduktion von zirkulierenden Autoantikörpern bzw. auf eine Depletion von autoreaktiven B-Zellen abzielen. Weitere zelluläre und molekulare Zielstrukturen werden in anderen Autoantikörper-vermittelten Autoimmunerkrankungen untersucht und stellen vielversprechende Kandidaten für innovative, pathogenesebasierte Therapiestrategien beim Pemphigus dar. Pemphigus is a severe bullous autoimmune dermatosis that represents a clinical challenge despite high-dose immunosuppressive therapy due to the therapy-related comorbidities and the lack of long-term control of disease activity. Which targeted therapies are currently used in pemphigus and which innovative therapeutic strategies are in clinical development? A review of the literature in PubMed was performed under consideration of the current guideline for the treatment of pemphigus as well as of our own results. Discussion of basic findings and results of targeted therapies in autoantibody-mediated autoimmune disorders were taken into account. Immunapheresis and high-dose intravenous immunoglobulins with the aim of reducing circulating autoantibodies have been successfully used in the treatment of pemphigus. Depletion of autoreactive B-lymphocytes provides the rationale for the use of the monoclonal anti-CD20 antibody rituximab which demonstrated long-term clinical remission of pemphigus in clinical trials. Current developments include the investigation of humanised B-cell depleting antibodies in other B-cell driven autoimmune disorders as well as the identification of new cellular and molecular target structures that are essential in the humoral autoimmune cascade and exert important immune regulatory functions, respectively. The well-characterised basic pathogenesis of pemphigus results in targeted therapies. Currently, therapies aiming at rapid reduction of circulating autoantibodies and the depletion of autoreactive B-cells are in clinical use. More cellular and molecular target structures are being investigated in other autoantibody-driven autoimmune disorders and they provide promising candidates for innovative pathogenesis-related therapeutic strategies in pemphigus in the future.
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 833-845
S2k‐Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoid
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 833-845
S2k‐Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoid
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 833-844
S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid
- 27 July 2015
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 13 (8) , 833-844
S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid
- Open Access
- 1 November 2014
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 193 (9) , 4391-4399
Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells
Pemphigus vulgaris (PV) is considered as a model for an autoantibody-mediated organ-specific autoimmune disorder. IgG autoantibodies directed against the desmosomal cadherin desmoglein 3 (Dsg3), the major autoantigen in PV, cause loss of epidermal keratinocyte adhesion, resulting in blisters and erosions of the skin and mucous membranes. The association of human autoimmune diseases with distinct HLA alleles is a well-known phenomenon, such as the association with HLA-DRB1*04:02 in PV. However, direct evidence that HLA-DRB1*04:02–restricted autoreactive CD4+ T cells recognizing immunodominant epitopes of Dsg3 initiate the production of Dsg3-reactive IgG autoantibodies is still missing. In this study, we show in a humanized HLA-DRB1*04:02–transgenic mouse model that HLA-DRB1*04:02–restricted T cell recognition of human Dsg3 epitopes leads to the induction of pathogenic IgG Abs that induce loss of epidermal adhesion, a hallmark in the immune pathogenesis of PV. Activation of Dsg3-reactive CD4+ T cells by distinct human Dsg3 peptides that bind to HLA-DRβ1*04:02 is tightly regulated by the HLA-DRB1*04:02 allele and leads, via CD40-CD40L–dependent T cell–B cell interaction, to the production of IgG Abs that recognize both N- and COOH-terminal epitopes of the human Dsg3 ectodomain. These findings demonstrate key cellular and humoral immune events in the autoimmune cascade of PV in a humanized HLA-transgenic mouse model. We show that CD4+ T cells recognizing immunodominant Dsg3 epitopes in the context of the PV-associated HLA-DRB1*04:02 induce the secretion of Dsg3-specific IgG in vivo. Finally, these results identify Dsg3-reactive CD4+ T cells as potential therapeutic targets in the future.
- 1 November 2014
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 193 (9) , 4391-4399
Open AccessPathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells
Pemphigus vulgaris (PV) is considered as a model for an autoantibody-mediated organ-specific autoimmune disorder. IgG autoantibodies directed against the desmosomal cadherin desmoglein 3 (Dsg3), the major autoantigen in PV, cause loss of epidermal keratinocyte adhesion, resulting in blisters and erosions of the skin and mucous membranes. The association of human autoimmune diseases with distinct HLA alleles is a well-known phenomenon, such as the association with HLA-DRB1*04:02 in PV. However, direct evidence that HLA-DRB1*04:02–restricted autoreactive CD4+ T cells recognizing immunodominant epitopes of Dsg3 initiate the production of Dsg3-reactive IgG autoantibodies is still missing. In this study, we show in a humanized HLA-DRB1*04:02–transgenic mouse model that HLA-DRB1*04:02–restricted T cell recognition of human Dsg3 epitopes leads to the induction of pathogenic IgG Abs that induce loss of epidermal adhesion, a hallmark in the immune pathogenesis of PV. Activation of Dsg3-reactive CD4+ T cells by distinct human Dsg3 peptides that bind to HLA-DRβ1*04:02 is tightly regulated by the HLA-DRB1*04:02 allele and leads, via CD40-CD40L–dependent T cell–B cell interaction, to the production of IgG Abs that recognize both N- and COOH-terminal epitopes of the human Dsg3 ectodomain. These findings demonstrate key cellular and humoral immune events in the autoimmune cascade of PV in a humanized HLA-transgenic mouse model. We show that CD4+ T cells recognizing immunodominant Dsg3 epitopes in the context of the PV-associated HLA-DRB1*04:02 induce the secretion of Dsg3-specific IgG in vivo. Finally, these results identify Dsg3-reactive CD4+ T cells as potential therapeutic targets in the future.
- Open Access
- 16 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e110138
CD3-Positive B Cells: A Storage-Dependent Phenomenon
The majority of clinical studies requires extensive management of human specimen including e.g. overnight shipping of blood samples in order to convey the samples in a central laboratory or to simultaneously analyze large numbers of patients. Storage of blood samples for periods of time before in vitro/ex vivo testing is known to influence the antigen expression on the surface of lymphocytes. In this context, the present results show for the first time that the T cell antigen CD3 can be substantially detected on the surface of human B cells after ex vivo storage and that the degree of this phenomenon critically depends on temperature and duration after blood withdrawal. The appearance of CD3 on the B cell surface seems to be a result of contact-dependent antigen exchange between T and B lymphocytes and is not attributed to endogenous production by B cells. Since cellular subsets are often classified by phenotypic analyses, our results indicate that ex vivo cellular classification in peripheral blood might result in misleading interpretations. Therefore, in order to obtain results reflecting the in vivo situation, it is suggested to minimize times of ex vivo blood storage after isolation of PBMC. Moreover, to enable reproducibility of results between different research groups and multicenter studies, we would emphasize the necessity to specify and standardize the storage conditions, which might be the basis of particular findings.
- 16 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e110138
Open AccessCD3-Positive B Cells: A Storage-Dependent Phenomenon
The majority of clinical studies requires extensive management of human specimen including e.g. overnight shipping of blood samples in order to convey the samples in a central laboratory or to simultaneously analyze large numbers of patients. Storage of blood samples for periods of time before in vitro/ex vivo testing is known to influence the antigen expression on the surface of lymphocytes. In this context, the present results show for the first time that the T cell antigen CD3 can be substantially detected on the surface of human B cells after ex vivo storage and that the degree of this phenomenon critically depends on temperature and duration after blood withdrawal. The appearance of CD3 on the B cell surface seems to be a result of contact-dependent antigen exchange between T and B lymphocytes and is not attributed to endogenous production by B cells. Since cellular subsets are often classified by phenotypic analyses, our results indicate that ex vivo cellular classification in peripheral blood might result in misleading interpretations. Therefore, in order to obtain results reflecting the in vivo situation, it is suggested to minimize times of ex vivo blood storage after isolation of PBMC. Moreover, to enable reproducibility of results between different research groups and multicenter studies, we would emphasize the necessity to specify and standardize the storage conditions, which might be the basis of particular findings.